Table 3 Association of Co-morbidities in MetS patients with risk of COVID-19.
Characteristic | MetS patients with COVID-19 (N = 206) | MetS patients without COVID-19 (N = 794) | OR (95% CI) | P value |
|---|---|---|---|---|
Obesity | 98 (47.6%)/108 (52.4%) | 247 (31.1%)/ 547 (68.9%) | 2.00 (1.47–2.74) | < 0.0001 |
CVD | 43 (20.1%)/ 163 (79.9%) | 111 (13.9%)/ 683 (86.1%) | 1.62 (1.09–2.40) | 0.0153 |
T2DM | 63 (30.5%)/ 143 (69.5%) | 187 (23.5%)/ 607 (76.5%) | 1.43 (1.01-2.00) | 0.0384 |
Dyslipidemia | 88 (42.7%)/ 118 (57.3%) | 263 (33.1%)/ 531 (66.9%) | 1.50 (1.10–2.05) | 0.0104 |
Neurodegenerative diseases | 5 (2.4%)/ 201 (97.6%) | 16 (2.1%)/ 778 (97.9%) | 1.20 (0.43–3.34) | 0.7136 |
Kidney diseases | 24 (11.6%)/ 182 (88.4%) | 63 (7.9%)/ 731 (92.1%) | 1.53 (0.93–2.51) | 0.0937 |
Hypothyroidism | 13 (6.3%)/ 193 (93.7%) | 48 (6.1%)/ 746 (93.9%) | 1.04 (0.55–1.97) | 0.8873 |
Hypertension | 81 (39.3%)/ 125 (60.7%) | 246 (30.1%)/ 548 (69.9%) | 1.44 (1.05–1.98) | 0.0234 |
Asthma | 23 (11.2%)/ 179 (88.8%) | 60 (7.5%)/ 734 (92.5%) | 1.84 (1.13–2.90) | 0.0129 |
Lung diseases | 66 (32.1%)/ 140 (67.9%) | 116 (14.6%)/ 678 (85.4%) | 2.75 (1.93–3.92) | < 0.0001 |